Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Quinolines (including hydrogenated)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514277000 - Hetero ring is six-membered consisting of one nitrogen and five carbon atoms

514279000 - Polycyclo ring system having the six-membered hetero ring as one of the cyclos

514299000 - Bicyclo ring system having the six-membered hetero ring as one of the cyclos

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514312000 Chalcogen attached directly to the six-membered hetero ring by nonionic bonding 239
514314000 Additional hetero ring attached directly or indirectly to the quinoline ring system by nonionic bonding 187
514313000 Nitrogen, other than as nitro or nitroso, attached directly to the six membered hetero ring by nonionic bonding 79
Entries
DocumentTitleDate
20090298872COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROIDAL RECEPTORS AND CALCIUM CHANNEL ACTIVITIES - The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorder associated with the activation of steroid hormone nuclear receptors.12-03-2009
20100152236Cyclic amine compound - A compound represented by the formula (I)06-17-2010
200902868282-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES - The present invention relates to compounds of formula (I), or to salts or solvates thereof, their use in the manufacture of medicaments for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder. The invention further comprises processes to make these compounds and pharmaceutical formulations thereof.11-19-2009
20090192190Benzoic Acid Derivatives that are Modulators or Agonists of GlyR - Compounds of formula I,07-30-2009
20130210860PROPHYLACTIC AND/OR THERAPEUTIC AGENT AGAINST LYMPHEDEMA - Provided is a new prophylactic and/or therapeutic agent for lymphedema, for which until now there has been no effective means of treatment, and the prophylactic and/or therapeutic agent for lymphedema comprises, as an active ingredient, a compound represented by the following formula (1), a lactone derivative thereof, or a salt of the compound or lactone derivative:08-15-2013
20100113513QUINOLINE DERIVATIVES AS FUNGICIDES - Compounds of the general formula (I) wherein the substituents are as defined in claim 05-06-2010
20100076017SITAMAQUINE TOSYLATE FOR THE TREATMENT OF LEISHMANIASIS - Disclosed in a novel compound of formula (IA) and its use in the treatment of leishmaniasis infections.03-25-2010
200802620334-Phenyl-5-Oxo-1,4,5,6,7,8- Hexahydroquinoline Derivatives as Medicaments for the Treatment of Infertility - The present invention- relates to 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives having the general Formula (I) wherein the substituents are defined as in the description, or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, as well as to the use of these 2-methyl-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives in therapy, more specifically for the treatment of fertility disorders.10-23-2008
20100105727NOVEL BENZAMIDE DERIVATIVES AND PROCESS FOR THE PREPARTION THEREOF - The present invention provides a novel benzamide derivative represented by formula 1 and an isomer, a pharmaceutically acceptable salt or hydrate thereof, and a composition for activating a 5-HT4 receptor comprising the same, as an active ingredient. Benzamide derivatives of the present invention has superior affinity for 5-HT4 receptors, capability to reduce the gastric evacuation time, capability to alleviate ventricular tachycardia, ventricular fibrillation, torsades de pointes and QT prolongation, and low toxicity. Therefore, benzamide derivatives of the present invention are therapeutically effective for digestive system diseases.04-29-2010
20090124656Heterocyclic Oxime Compounds a Process for Their Preparation and Pharmaceutical Compositions Containing Them - Compounds of formula (I):05-14-2009
20090124658Treatments for Viral Infections - The present invention relates to improved methods and compositions for treating viral infections and other diseases and conditions that induce a cytokine storm. More particularly, the present invention relates to novel compositions comprising quercitin, and an anti-convulsant, such as phenyloin, in combination with multivitamins as an anti-viral composition and methods of use thereof.05-14-2009
20090326007Compounds and methods for modulating sir2 protein activity - The present invention embraces compounds that modulate the activity of sirtuin deacetylase protein family members and use thereof for modulating Sir2 activity as well as for preventing or treating diseases or disorders associated with Sir2.12-31-2009
20090306132USE OF DERIVATIVES OF NAPHTHALENESULPHONIC OR QUINOLINESULPHONIC ACID IN THE TREATMENT OF VASOPROLIFERATIVE OCULAR DISEASES - The invention relates to the use of derivatives of sulphonic acid (I) or one of the pharmaceutically-acceptable prodrugs or salts thereof in the preparation of a medicament for the treatment of vasoproliferative ocular diseases, said sulphonic acid having formula (I).12-10-2009
20130059885Method For Preparation Of Pitavastatin and Pharmaceutical Acceptable Salts Thereof - The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.03-07-2013
20130059884INHIBITOR OF THE DIFFERENTIATION OF T CELLS INTO TH1 CELLS - The present invention is to provide an inhibitor that inhibits differentiation of T cells into Th1 cells.03-07-2013
20110021560Compositions And Methods For Regulating Chondrocyte Proliferation In Bone Disorders - The present invention is related to the field of cartilage physiology, repair, and regeneration. In particular, the invention contemplates a treatment for bone healing disorders, especially those related to the articular joints and bone, by upregulating chondrocyte proliferation. For example, inhibition of cysteinyl leukotriene activity on chondrocytes by using cysteinyl leukotriene-1 receptor antagonists may be useful in preventing and treating bone healing disorders. This invention also relates to other physiologic conditions which are influenced by chondrocyte activity, including pediatric long bone growth and neoplastic conditions involving cells of chondrogenic origin01-27-2011
20110046177THERAPEUTIC QUINOLINE AND NAPHTHALENE DERIVATIVES - Disclosed herein is a stable compound having a structure formula (I): therapeutic methods, compositions, and medicaments related thereto are also disclosed.02-24-2011
20100087480SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS - This invention provides a compound of the formula (I). These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.04-08-2010
20080293764LPA RECEPTOR ANTAGONIST - A compound of the general formula (I):11-27-2008
20100076018Compounds and Methods for Treatment of Alpha-1 Antitrypsin Deficiency - The invention features compositions and methods that are useful for treating or preventing AAT deficiency and associated conditions. In addition, the invention provides methods for identifying compounds useful for treatment of AAT deficiency and associated conditions.03-25-2010
20090124657PHARMACEUTICAL COMPOSITIONS COMPRISING MONTELUKAST - Pharmaceutical compositions comprising montelukast or pharmaceutically acceptable salts, solvates, polymorphs, enantiomers or mixtures thereof.05-14-2009
201101441558-HYDROXYQUINOLINE DERIVATIVES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES - The application relates to compositions and methods for treating hematological malignancies and proliferative diseases, disorders and conditions involving increased D-cyclin expression. In particular, the application relates to compositions and methods for treating the hematological malignancies acute myeloid leukemia (AML), lymphoma and multiple myeloma (MM) using 5-nitrogen substituted hydroxy quinolones as well as 7-bromo-5-chloro substituted hydroxy quinolones and 5-chloro substituted hydroxy quinolones.06-16-2011
20090093519Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase - Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3′,5′-adenosine monophosphate. Specific compositions of the invention are also novel.04-09-2009
20100280068QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES - Compounds of the general Formula (1) wherein the substituents are as defined in claim 11-04-2010
20090111849CRYSTALLINE SALT OF MONTELUKAST - Cyclopropylamine salt of montelukast in crystalline form and its use for the preparation of highly pure amorphous montelukast sodium.04-30-2009
20080312273Quinoline Derivatives Having Vegf Inhibiting Activity - The invention relates to compounds of formula (I) wherein: either any one of G12-18-2008
20100120848STABLE PHARMACEUTICAL FORMULATIONS OF MONTELUKAST SODIUM - The invention encompasses stable pharmaceutical compositions comprising montelukast or salts thereof and methods of preparing the same.05-13-2010
20120108630Hedgehog Pathway Antagonists and Methods of Use - The present disclosure provides for compounds, pharmaceutical preparations, kits and methods for the inhibition of the Hh pathway and the alleviation of cancer and developmental disorders associated with the Hh pathway.05-03-2012
20100081688Process for the preparation of montelukast, and intermediates therefor - The invention relates to processes for making montelukast and to intermediates for use in the process, in particular compounds of formulas 2-7: L=OAc, OTs, OTf5OMs; where X=Cl, Br, I.04-01-2010
20120295935MIXED AMINAL PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - Described herein are pharmaceutical compositions for the administration of one or more mixed aminals, as defined herein, including salubrinal and analogs and derivatives of salubrinal, and methods for treating diseases or disorders arising from apoptosis, particularly for treating diseases or disorders arising from integrated stress response-induced apoptosis, such as occurs in bone diseases, injuries, and defects.11-22-2012
20110172267TSH receptor antagonizing tetrahydroquinoline compounds - The present invention relates the use of a compound, a pharmaceutical composition, compounds and a kit for treating or preventing disorders in a mammal responsive to TSH receptor mediated pathways, including disorders such as hyperthyroidism, Graves' disease, Graves Ophthalmopathy, Graves' associated pretibial dermopathy, nodular goitre and thyroid cancer comprising administering to said mammal an effective amount of a tetrahydroquinoline compound of Formula (I) or an pharmaceutically acceptable salt thereof.07-14-2011
20080275081Novel thrombomodulin expression promoters - It is intended to provide a novel pharmaceutical effect of HMG-COA reductase inhibitors, in particular, (+)-(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-di hydroxy-6-heptenoic acid or its salt. Namely, TM expression promoters, more specifically speaking, antithrombotic drugs, preventive/remedies for sepsis, antiplatelet drugs and anticoagulants comprising as the active ingredient an HMG-COA reductase inhibitor, in particular, (+)-(3R, 5S, 6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid or its salt.11-06-2008
20090149496INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL - The invention relates to the use of Kv1.5 inhibitors for the therapy or prophylaxis of respiratory disorders, sleep-related respiratory disorders, central and obstructive sleep apneas, upper airway resistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, muscle-related respiratory disorders, respiratory disorders after long-term ventilation, respiratory disorders during adaptation in high mountains, acute and chronic lung disorders with hypoxia and hypercapnia, neurodegenerative disorders, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cancer disorders, breast cancer, lung cancer, colon cancer and prostate cancer.06-11-2009
20080269283ARYLSULFONES AND USES RELATED THERETO - Aryl sulfone compounds of formula I and II are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:10-30-2008
20090264463Inhibitors Of Protein Phosphatase-1 And Uses Thereof - Inhibitors of Protein Phosphatase-1 have been shown to slow replication of HIV-1. Inhibitors of PP 1 and their use for treatment or prevention of HIV-1 infections are disclosed.10-22-2009
20080269282Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof - This invention is directed to inhibitors of copper-containing amine oxidases (E.C.1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-I), and their therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer.10-30-2008
20120196892NOVEL CASPASE-2 INHIBITORS - Novel compounds of formula (I) and slats thereof and pharmaceutical compositions which contain such a compound or salt are useful for inhibiting pro-apoptotic caspase-2 and for preventing and/or treating diseases and injuries where caspase-2 activity is implicated, in particular neonatal brain ischemia.08-02-2012
20090163543Histone Deacetylase Inhibitors and Methods of Use Thereof - One aspect of the invention relates to HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided. The invention also provides methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.06-25-2009
20090054482Method of making and administering quinoline derivatives as anti-cancer agents - The present invention relates methods of preparing quinoline derivative compounds, and administering such compounds in the treatment of solid and non-solid tumors, notably on liver cancer.02-26-2009
20090023772Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors - This invention relates to novel substituted heteroaryloxy alkylamines useful as monoamine neurotransmitter re-uptake inhibitors.01-22-2009
20110144154Salts of 2-Substituted Quinolines - The invention relates to salts of 2-substituted quinolines, the manufacturing method for same, and use of the same for the production of drugs. Said salts are advantageous in that the same can be obtained in crystalline form, which facilitates their implementation in the manufacture of pharmaceutical compositions.06-16-2011
20080319007DEUTERIUM-ENRICHED MONTELUKAST - The present application describes deuterium-enriched montelukast, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.12-25-2008
20120196893COMPOSITION, METHOD, SYSTEM AND KIT FOR OPTICAL ELECTROPHYSIOLOGY - The present invention provides a method of optical electrophysiological probing, including: providing a fluorescing chemical probe; contacting a thick portion of tissue with the fluorescing chemical probe to create a thick portion of treated tissue; applying a first range of wavelengths of electromagnetic radiation to the treated portion of tissue; and detecting a plurality of depth-specific emission wavelengths emitted from the thick portion of treated tissue.08-02-2012
20100160371INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS - This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases other than cancer and proteolytic enzyme mediated diseases other than cancer, and pharmaceutical compositions for use in such therapy.06-24-2010
20090318496PREPARATION CONTAINING FIBRATE AGENT AND PROCESS FOR PRODUCING THE SAME - A preparation (pharmaceutical composition) reducing a concentration of a free fatty acid and/or fibrinogen in the blood is prepared. The preparation contains a statin agent comprising at least a statin compound having a benzopyridine skeleton (e.g., pitavastatin) and a fibrate agent (e.g., fenofibrate). The preparation is useful as a preventive or treating agent for hyper-free fatty acidemia, metabolic syndrome, or type II diabetes.12-24-2009
20090318495ETHENYL CARBOXAMIDE DERIVATIVES USEFUL AS MICROBIOCIDES - Compounds of the formula (I), which are suitable for use as microbiocides, and in which A is A12-24-2009
20090298873METHODS OF REDUCING MICROBIAL RESISTANCE TO DRUGS - The instant methods and compositions represent an advance in controlling drug resistance in microbes. AcrAB-like efflux pumps have been found to control resistance to drugs, even in highly resistant microbes. Accordingly, methods of treating infection, methods of screening for inhibitors of AcrAB-like efflux pumps, and methods of enhancing antimicrobial activity of drugs are provided. Pharmaceutical composition comprising an inhibitor of an AcrAB-like efflux pump and an antimicrobial agent are also provided.12-03-2009
20100197726INHIBITOR OF THE DIFFERENTIATION OF T CELLS INTO TH1 CELLS - The present invention is to provide an inhibitor that inhibits differentiation of T cells into Th1 cells.08-05-2010
20120142728CHEMICAL COMPOUND AND ITS USE - The present application relates to a novel tetrahydroquinoline derivative, to a process for its preparation, to its use on its own or in combination for treating and/or preventing diseases and to its use for preparing medicaments, in particular as an inhibitor of the cholesterol ester transfer protein (CETP) for the treatment and/or prevention of cardiovascular disorders, in particular hypolipoproteinaemias, dyslipidaemias, hypertriglyceridaemias, hyperlipidaemias, hypercholesterolaemias and arteriosclerosis.06-07-2012
20100222379NOVEL HISTONE DEACETYLASE INHIBITORS - Provided herein are novel, stilbene like compounds of the general formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, metabolites, prodrugs, solvates, pharmaceutically acceptable salts and compositions thereof. These compounds can inhibit HDACs and are useful as a therapeutic or ameliorating agent for diseases that are involved in cellular growth such as WO 2009/047615 A2 malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, etc.09-02-2010
20110112140INHIBITOR OF PLASMINOGEN ACTIVATOR INHIBITOR-1 - The present invention relates to a novel compound having plasminogen activator inhibitor-1 (PAI-1) inhibitory activity, and a PAI-1 inhibitor comprising the compound as an active ingredient. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. The novel compound is represented by the following general formula.05-12-2011
20100227884AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME - The object of the present invention is to provide a compound having excellent controlling effect on plant diseases. An amide compound represented by the following formula (I) has excellent controlling effect on plant diseases:09-09-2010
20080207686Peptide Deformylase (Pdf) Inhibitors 4 - The present invention relates to compounds of formula (I).08-28-2008
20090143425COMPOUNDS AFFECTING GAP JUNCTION ACTIVITY - This invention relates to novel quinoline compounds which affect gap junction activity. Also provided are methods of using such compounds and compositions containing the compounds to treat gap junction disorders.06-04-2009
20110118307Compositions and methods for the treatment of infectious diseases - Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.05-19-2011
20130137720HISTONE DEMETHYLASE INHIBITORS AND METHODS FOR USING THE SAME - The present invention provides compounds, or derivatives or prodrugs thereof, that comprise a methyllysine mimic, and an α-ketoglutarate mimic that are attached through a linker and methods for using and producing the same. In some embodiments, compounds of the invention are of the formula: M-L-K, or a derivative or a prodrug thereof, wherein M is a methyllysine mimic, L is a linker, and K is an α-ketoglutarate mimic.05-30-2013
20100311790AMIDE COMPOUNDS AND PLANT DISEASE CONTROLLING METHOD USING SAME - The object of the present invention is to provide a compound having excellent controlling effect on plant diseases. An amide compound represented by the following formula (I) has excellent controlling effect on plant diseases:12-09-2010
20110124681TOPICAL AND INJECTABLE FORMULATIONS COMPRISING LEUKOTRIENE RECEPTOR ANTAGONIST AND USES THEREOF - Methods of treating, preventing, reducing the occurrence of, or slowing progression of folliculitis, partial or full hair loss, thinning of the hair, changes in the texture of hair, graying or whitening (loss of pigmentation) of the hair, dermatological conditions, and other hair-related conditions, comprising administering topical and injectable formulations containing one or more leukotriene receptor antagonists.05-26-2011
20090247575STABILIZING LIPID COMPOSITIONS FOR ORAL PHARMACEUTICAL AGENTS - The present invention relates to a pharmaceutical composition for oral administration comprising an exceptionally labile active agent, a stabilizing vehicle comprising liquid triglycerides and a desiccant, wherein the composition is storage stable for an extended period without substantial degradation of the active agent.10-01-2009
20090036484Use of Unsaturated Quionoline or Naphtalene Derivatives as Medicaments - A compound of formula (I): (I), or a pharmaceutically acceptable salt thereof; for use as a medicament (for example modulating the glucocorticoid receptor in a warm blooded animal), and pharmaceutical compositions comprising such compounds.02-05-2009
20090215819ANTI-INFECTIVE AND IMMUNOMODULATORY COMPOUNDS - The present invention provides pharmaceutical compositions and methods that include the use of anti-infective compounds that potentiate the host-immune response or limit or prevent the expression or activity of individual virulence factors. In addition, the compositions have immunomodulatory activity, and therefore can be used to prime host defenses to prevent or limit bacterial, fungal, and viral viability. In the compositions and methods of the inventions, specific steps of the bacterial-, fungal-, or viral-host interaction are targeted to prevent pathogenesis (e.g., infection). Such an approach should prevent pathogenic organisms from acquiring resistance to the protective anti-infective compounds.08-27-2009
20100069433PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR HYPERLIPIDEMIA - The present invention provides a therapeutic agent for hyperlipidemia having an excellent effect of lowering the cholesterol and triglyceride level in blood plasma.03-18-2010
20080255189HEPATITIS C VIRUS INHIBITORS - A compound of the following formula:10-16-2008
20090275611Compounds Which Modulate The CB2 Receptor - Compounds are provided which bind to and are agonist, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein R11-05-2009
20100120847STYRYLQUINOLINES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTIC USES - The present invention concerns new substituted styrylquinolines, their process of preparation and their therapeutic uses as integrase inhibitors and/or for the treatment and/or prevention of HIV.05-13-2010
20090030037Sustained Release Formulation and Dosing Schedules of Leukotriene Synthesis Inhibitor for Human Therapy - The invention relates to materials and methods for therapy to inhibit the production of leukotrienes, and therapeutic and prophylactic applications thereof.01-29-2009
20110152315COMPOUNDS FOR THE TREATMENT OF METABOLIC DISEASES - There is provided novel compounds capable of modulating the G-protein-coupled receptor GPR40, compositions comprising the compounds, and methods for their use for controlling insulin levels in vivo and for the treatment of conditions such as type I1 diabetes, hypertension, ketoacidosis, obesity, glucose intolerance, and hypercholesterolemia and related disorders associated with abnormally high or low plasma lipoprotein, triglyceride or glucose levels.06-23-2011
20120122920LIBRARIES OF N-SUBSTITUTED-N-PHENYLETHYLSULFONAMIDES FOR DRUG DISCOVERY - New compounds are continually being sought for the treatment and prevention of disorders. The invention relates to N-substituted-N-phenylethylsulfonamides libraries which can be used in the search for, and identification of, new lead compounds that could modulate the functional activity of a biological target.05-17-2012
20100286199NOVEL FUNGICIDES - Fungicidal compounds of the general formula (I), wherein the substituents are as defined in claim 11-11-2010
20110257225CYCLOHEXYLAMINE DERIVATIVE CONTAINING PHENYL GROUP, AND THERAPEUTIC AGENT FOR DISEASES ACCOMPANIED BY CENTRAL NERVOUS SYSTEM DISORDERS - Disclosed is a novel cyclohexylamine derivative containing a phenyl group, which is useful as a novel sigma receptor ligand. Also disclosed is a therapeutic agent for diseases accompanied by a central nervous system disorder, which comprises the compound as an active ingredient. The therapeutic agent comprises a compound represented by general formula [1] or a pharmacologically acceptable salt thereof as an active ingredient:10-20-2011
20100305154Prolyl Hydroxylase Inhibitors - The invention described herein relates to certain quinoline-8-carboxamide derivatives of formula (I)12-02-2010
20100222380Modified Chalcone Compounds as Antimitotic Agents - Antimitotic agents comprising a modified chalcone or modified chalcone derivative are disclosed. The modified chalcone or modified chalcone derivative compounds are of the general formula CHAL-LIN-COV, wherein CHAL is a chalcone or chalcone derivative portion, LIN is an optional linker portion, and COV is a covalent bonding portion (e.g., an α,β-unsaturated thiol ester group). The modified chalcone or modified chalcone derivative compounds provide an improved method of interference with tubulin polymerization, for example by covalent (and essentially irreversible) bonding between tubulin and the covalent bonding portion, potentially resulting in a decrease in tumor size and/or disappearance of the cancer, to the benefit of cancer patients.09-02-2010
20100125090Modulators of ATP-Binding Cassette Transporters - The present invention provides compounds of Formula I useful as modulators of ABC transporter activity,05-20-2010
20120041023SMALL MOLECULE ACTIVATORS OF MITOCHONDRIAL FUNCTION - Methods for improving mitochondrial function, decreasing iron accumulation, and/or decreasing oxidative stress by exposing cells or treating a subject to compounds or compositions of the general formula (I) are described that are beneficial in treating, for example, diseases and conditions such as Friedreich's ataxia, normal aging, and various neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Furthermore, such compounds are useful as probes for identifying defects in mitochondrial metabolism, mitochondrial iron accumulation, cellular stress among other mitochondrial diseases and helping to identify compounds active in overcoming such defects.02-16-2012
20100210683IMIDATE COMPOUND AND USE THEREOF FOR PEST CONTROL - There is provided a compound having an excellent controlling effect on arthropod pests represented by the formula (I-1):08-19-2010
20090005413Novel Salt of Montelukast - The invention relates to a novel salt of montelukast with tert-butylamine and its use in the process for the preparation of highly pure free montelukast acid and/or pharmaceutically acceptable salts thereof, in particular montelukast sodium.01-01-2009
20120004262PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE - The present invention relates to phenylcyclopropylamine derivatives. In particular, pharmaceutical compositions comprising phenylcyclopropylamine derivatives are provided. The compounds of this invention can, inter alia, be used for the treatment and the prevention of cancer as well as neurodegenerative diseases or disorders.01-05-2012
20120022102METHOD FOR PREPARATION OF PITAVASTATIN AND ITS PHARMACEUTICAL ACCEPTABLE SALTS THEREOF - The present invention discloses a compound, which is alkali or alkaline earth metal salts of pitavastatin, wherein the alkali or earth metal comprise one or more of magnesium, zinc, potassium, strontium and barium.01-26-2012
20120129887COMPOUNDS DERIVED FROM ARTESUNATE, PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION AND USE OF THE RESPECTIVE MEDICINE - The present invention refers to new compounds represented by the general formula (I) where X is represented by the general formula (II) and Y is represented by the general formula (III). The relation X to Y may vary from 1:1 to 1:7. The radicals R05-24-2012
20100173938NERVE CELL DEATH INHIBITOR - The present invention provides a medicament exhibiting an excellent nerve cell death inhibitory action.07-08-2010
20090018161METHOD FOR PROMOTING GASTROINTESTINAL FUNCTION AND METHOD FOR SCREENING FOR PROMOTER OF GASTROINTESTINAL FUNCTION - The present invention provides a more effective gastrointestinal function promoter. The present invention also provides a method for the prophylaxis or improvement of functional gastrointestinal disorders, a method for appetite regulation and the like. The present invention also provides a method for screening for a substance capable of promoting a gastrointestinal function. The present invention provides a gastrointestinal function promoter containing a T1R agonist as an active ingredient and a method for the prophylaxis or improvement of functional gastrointestinal disorders, a method for appetite regulation and the like by administering a T1R agonist. The present invention also provides a method of screening for a substance capable of promoting a gastrointestinal function which method uses a cell expressing T1R receptor.01-15-2009
20080300271Novel compounds and a novel process for their preparation - The present invention is directed to a procedure for making an enantidimerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nuclophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions.12-04-2008
200803002704-Phenyl-5-Oxo-1,4,5,6,7,8,- Hexahydroquinoline Derivatives as Medicaments for the Treatment of Infertility - The invention relates to a 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivative according to Formula (I), wherein the substituents are defined as in the description, or a pharmaceutically salt thereof. The compounds of this invention are potent FSH receptor activators and may be used for treating fertility disorders in e.g. controlled ovarian hyperstimulation and IVF procedures.12-04-2008
20100022584Modulation of Glutamine Synthetase Activity - Methods of screening and designing compounds as inhibitors of glutamine synthetase are provided herein. Compounds, e.g., serine protease inhibitors, and compositions comprising the same, that are useful for the treatment, prevention, and/or amelioration of bacterial infections, including 01-28-2010
20120101126CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM - The present invention is directed to new crystalline forms of Pitavastatin hemicalcium salt, referred to hereinafter as polymorphic Forms A, B, C, D, E and F, as well as the amorphous form. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and the amorphous form and pharmaceutical compositions comprising these crystalline forms or the amorphous form.04-26-2012
20130012536MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS - The present invention provides compounds of Formula I useful as modulators of ABC transporter activity,01-10-2013
20090291980TRIGLYCERIDE-LOWERING AGENT AND HYPERINSULINISM-AMELIORATING AGENT - The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent.11-26-2009
20080221157Amide Derivatives as Inhibitors of Histone Deacetylase - The present invention relates to ketone derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.09-11-2008
20110269793METHOD FOR PREVENTING TAU PROTEIN AGGREGATION AND TREATING ALZHEIMER'S DISEASE WITH A QUINOLINE DERIVATIVE COMPOUND - Method for the prevention of the tau protein aggregation and treating Alzheimer's disease by administering a quinoline derivative compound of formula11-03-2011
201301377216-AMINOISOQUINOLINE COMPOUNDS - 6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.05-30-2013
20130096156QUINOLINE DERIVATIVES AS FUNGICIDES - Compounds of the general formula (I) wherein the substituents are as defined in claim 04-18-2013
20130143917(2E)-3-PHENYL-N-[2,2,2-TRIFLUORO-1-[[8-QUINOLINEAMINO)THIOMETHYL]AMINO]ETH- YL]-2-ACRYLAMIDE AND PHARMACEUTICAL USES THEREOF - The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosis06-06-2013
20080200502METHODS OF LOWERING LIPID LEVELS IN A MAMMAL - This invention relates to methods for lowering lipid levels in mammals using compounds that inhibit advanced glycation endproducts (AGEs), LR-9, LR-74 and LR-90. These compounds, which inhibit non-enzymatic protein glycation, also inhibit the formation of advanced lipoxidation endproducts (ALES) on target proteins by trapping intermediates in glycoxidation and lopoxidation and inhibiting oxidation reactions important in the formation of AGEs and ALEs.08-21-2008
20090018162USE OF 6-(3-CHLORO-2-FLUOROBENZYL)-1-[(2S)-1-HYDROXY-3-METHYLBUTAN-2-YL]-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID OR SALT THEREOF FOR TREATING RETROVIRUS INFECTION - The present invention provides a use of a therapeutically effective amount of 6-(3-chloro-2-fluorobenzyl)-01-15-2009
20130123300UREA COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS - A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.05-16-2013
20110319445HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS - Described herein are heteroaryl compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.12-29-2011
20120029013DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS - The present invention concerns compounds of general formula (1), where in:—-a- is a single or double bond, Ar is an aromatic group, substituted or unsubstituted, R1 and R2 each independently or together are: a hydrogen atom or C02-02-2012
20120095043TRIGLYCERIDE-LOWERING AGENT AND HYPERINSULINISM-AMELIORATING AGENT - The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent.04-19-2012
20120095042Organic Compounds Having Cooling Properties - Provided are compounds of formula (I)04-19-2012

Patent applications in class Quinolines (including hydrogenated)

Patent applications in all subclasses Quinolines (including hydrogenated)